In K562 leukemia cells, 24-hour SJB2-043 exposure reduced survival and increased apoptosis. The authors reported a survival EC50 of approximately 1.07 μM ± 0.08, with the uncertainty described as 95% confidence limits. [1]
In A549 lung cancer cells, SJB2-043 decreased the CCK-8 viability readout after 24 hours across the unambiguous 0.625–10 μM test groups. These cellular observations do not by themselves establish a USP1-specific mechanism. [2]
Native USP1 activity-probe competition after K562 treatment
Biochemical assay · Native USP1 in extracts of human K562 leukemia cells [1]
SJB2-043 treatment reduced formation of the USP1–Ub-VS adduct relative to DMSO. Ub-aldehyde served as a nonspecific DUB-inhibition control. Anti-HA signals show that effects were not confined to a demonstrated single DUB.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 μM
- Exposure duration
- 24 h cell treatment; 45 min probe incubation
- Method
- Cell pretreatment followed by lysate activity-probe labeling with 0.5 μM Ub-VS
- Vehicle
- DMSO; final fraction not specified
- Reported limits
- Replicate count and quantitative labeling inhibition are not stated in the adopted caption. This lysate endpoint does not establish selective binding or a binding site.
Methods and source locations
Compound reported in the paper: SJB2-043
Applies to the reported SJB2-043 research compound; supplier or Adooq lot equivalence is not established.
Figure 1H–I and caption; Results: USP1 inhibitor SJB2-043 inhibits the enzyme activity of native USP1; In Vitro Deubiquitination Assays
USP1 labeling with HA-Ub-VS: Anti-USP1 and anti-HA immunoblotting; untreated extract with and without probe and Ub-aldehyde control — Figure 1H–I and caption; Results: USP1 inhibitor SJB2-043 inhibits the enzyme activity of native USP1; In Vitro Deubiquitination Assays
K562 survival and apoptosis concentration response
Cell-based study · Human K562 leukemia cells [1]
After 24 h, SJB2-043 reduced viable K562 cell numbers and increased apoptosis with increasing concentration compared with DMSO. The reported survival EC50 is distinct from enzyme IC50.
Literature-Reported Treatment Conditions
- Treatment concentration
- Concentration response through 10 μM (Figure 2D–E); EC50 is an endpoint, not a fixed treatment dose
- Exposure duration
- 24 h
- Method
- Cells grown in triplicate with SJB2-043 or DMSO
- Vehicle
- DMSO; final fraction not specified
- Reported limits
- Caption reports triplicate; biological versus technical replication is not specified. No exact apoptosis percentages transcribed from graph.
Methods and source locations
Compound reported in the paper: SJB2-043
Applies to the reported SJB2-043 research compound; supplier or Adooq lot equivalence is not established.
Figure 2D–E and caption; Results: USP1 inhibitors are cytotoxic to leukemic cells; Cells and drug treatments
K562 survival: Viable-cell assay; shared methods list Trypan blue, CellTiter-Glo or MTT without assigning a specific one to panel D. Apoptosis assessed by Annexin V/7AAD flow cytometry. — Figure 2D–E and caption; Results: USP1 inhibitors are cytotoxic to leukemic cells; Cells and drug treatments
A549 cell viability after 24-hour exposure
Cell-based study · Human A549 lung cancer cells [2]
SJB2-043 reduced the CCK-8 viability readout with increasing concentration. Analysis is restricted to the unambiguous 0.625, 2.5 and 10 μM groups versus the zero-compound control. Figure caption reports mean ± SD, n = 9; the independence of those replicates is unspecified.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.625, 2.5 and 10 μM; 0 μM control
- Exposure duration
- 24 h exposure; 2 h CCK-8 incubation
- Method
- CCK-8 viability assay
- Vehicle
- Not specified in the read methods
- Reported limits
- Methods list 0.39 μM whereas Figure 3A labels 0.039 μM; that low-dose group is excluded. No IC50 is given for this adopted endpoint. This viability assay does not prove USP1-specific causality. Colony formation in panel B is excluded because its dose labels conflict with Methods 2.6.
Methods and source locations
Compound reported in the paper: SJB2-043
Named SJB2-043 in A549 cells; no Adooq material validation.
Methods 2.1, 2.2, 2.5 and 2.11; Results 3.3; Figure 3A and caption
A549 CCK-8 viability relative to control: CCK-8 absorbance at 450 nm after 24 h treatment and 2 h reagent incubation; Figure 3A reports mean ± SD, n = 9, one-way ANOVA — Methods 2.1, 2.2, 2.5 and 2.11; Results 3.3; Figure 3A and caption